Top

Published in:

01-11-2011 | Progress in Hematology

Current status of HTLV-1 infection

Author: Toshiki Watanabe

Published in: International Journal of Hematology | Issue 5/2011

Abstract

It is 30 years since human T-cell leukemia virus type 1 (HTLV-1) was identified as the first human retrovirus. To assess the implications of the virus for human health it is very important to know the past and present prevalence. Most of the estimates of HTLV-1 prevalence are based on serological screening of blood donors, pregnant women and other selected population groups. The widely cited estimate that the number of HTLV-1 carriers in Japan is 1.2 million was calculated from data that are now more than 25 years old. Here I summarize previous reports of prevalence studies in the world and Japan. Then, a recent analysis of seroprevalence of healthy blood donors in Japan will be described in comparison with that of 1988. A decrease in the number of HTLV-1 carriers in Japan was demonstrated, however, it is still more than one million. The number has increased in the metropolitan areas, probably reflecting the migration of Japanese population. I conclude that there is a paucity of general population data in countries where HTLV-1 is endemic, and re-evaluation of HTLV-1 infection is required to understand the virus burden on the human health.

Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481–92.PubMed

Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415–9.PubMedCrossRef

Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981;78:6476–80.PubMedCrossRef

Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature. 1981;294:770–1.PubMedCrossRef

Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031–5.PubMedCrossRef

Watanabe T, Seiki M, Yoshida M. Retrovirus terminology. Science. 1983;222:1178.PubMedCrossRef

Gallo RC. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene. 2005;24:5626–930.CrossRef

Mahieux R, Gessain A. The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family. Pathol Biol (Paris). 2009;57:161–6.CrossRef

Ono A, Miura T, Araki S, Yamaguchi K, Takatsuki K, Mori S, et al. Subtype analysis of HTLV-1 in patients with HTLV-1 uveitis. Jpn J Cancer Res. 1994;85:767–70.PubMedCrossRef

10.

de Thé G, Kazanji M. An HTLV-I/II vaccine: from animal models to clinical trials? J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(Suppl 1):S191–8.PubMedCrossRef

11.

Inaba S, Sato H, Okochi K, Fukada K, Takakura F, Tokunaga K, et al. Prevention of transmission of human T lymphotropic virus type 1 (HTLV-1) through transfusion, by donor screening with antibody to the virus. One-year experience. Transfusion. 1989;29:7–11.PubMedCrossRef

12.

Goncalves DU, Proietti FA, Ribas JGR, Araujo MG, Pinheiro SR, Guedes AC, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23:577–89.PubMedCrossRef

13.

Proietti FA, Anna Bárbara, Carneiro-Proietti F, Bernadette C, Catalan-Soares, Murphy EL, et al. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24:6058–68.PubMedCrossRef

14.

Hinuma Y, Komoda H, Chosa T, Kondo T, Kohakura M, Takenaka T, et al. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer. 1982;29:631–5.PubMedCrossRef

15.

Satake M, Yamaguchi K. Annual report of the group study for survey of HTLV-1 infection and HTLV-1 related diseases in Japan. 2009 (in Japanese) (Manuscript submitted).

16.

Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer. 1990;45:237–43.PubMedCrossRef

17.

Kohakura M, Nakada K, Yonahara M, Komoda H, Imai J, Hinuma Y. Seroepidemiology of the human retrovirus (HTLV/ATLV) in Okinawa where adult T-cell leukemia is highly endemic. Jpn J Cancer Res. 1986;77:21–3.PubMed

18.

Tajima K, Kamura S, Ito S, Ito M, Nagatomo M, Kinoshita K, Ikeda S. Epidemiological features of HTLV-I carriers and incidence of ATL in an ATL-endemic island: a report of the community-based co-operative study in Tsushima, Japan. Int J Cancer. 1987;40:741–6.PubMedCrossRef

19.

20.

Chiyoda S, Kinoshita K, Egawa S, Inoue J, Watanabe K, Ifuku M. Decline in the positive rate of human T-lymphotropic virus type-1 (HTLV-1) antibodies among blood donors in Nagasaki. Intern Med. 2001;40:14–7.PubMedCrossRef

21.

Lee SY, Mastushita K, Machida J, Tajiri M, Yamaguchi K, Takatsuki K. Human T-cell leukemia virus type I infection in hemodialysis patients. Cancer. 1987;60:1474–8.PubMedCrossRef

22.

Iida S, Fujiyama S, Yoshida K, Morishita T, Shibata J, Sato T, et al. The seroprevalence of anti-HTLV-1 antibodies in patients with various liver diseases. Hepatogastroenterol. 1988;35:242–4.

23.

Kwon KW, Yano M, Sekiguchi S, Iwanaga M, Fujiwara S, Oikawa O, et al. Prevalence of human T-cell leukemia virus type 1 (HTLV-I) in general inhabitants in non-adult T-cell leukemia (ATL)-endemic Hokkaido, Japan. In Vivo. 1994;8:1011–4.PubMed

24.

Barcellos NT, Fuchs SC, Mondini LG, Murphy EL. Human T lymphotropic virus type I/II infection: prevalence and risk factors in individuals testing for HIV in counseling centers from Southern Brazil. Sex Transm Dis. 2006;33:302–6.PubMedCrossRef

25.

Ishida T, Yamamoto K, Kaneko R, Tokita E, Hinuma Y. Seroepidemiological study of antibodies to adult T-cell leukemia virus-associated antigen (ATLA) in free-ranging Japanese monkeys (Macaca fuscata). Microbiol Immunol. 1983;27:297–301.PubMed

26.

Hayami M, Komuro A, Nozawa K, Shotake T, Ishikawa K, Yamamoto K, et al. Prevalence of antibody to adult T-cell leukemia virus-associated antigens (ATLA) in Japanese monkeys and other non-human primates. Int J Cancer. 1984;33:179–83.PubMedCrossRef

27.

Tajima K, Itoh S, Itoh T, Kinoshita K, Shimotohno K. Epidemiology of ATL and HTLV-1. In: the annual report of the group study “Inhibition of mother-to-child infection and ATL” (1990). 1991 (in Japanese).

28.

Uchimaru K, Nakamura Y, Tojo A, Watanabe T, Yamaguchi K. Factors predisposing to HTLV-1 infection in residents of the greater Tokyo area. Int J Hematol. 2008;88:565–70.PubMedCrossRef

29.

Astier-Gin T, Portail JP, Londos-Gagliardi D, Moynet D, Blanchard S, Dalibart R, et al. Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states. J Infect Dis. 1997;175:716–9.PubMedCrossRef

30.

Londos-Gagliardi D, Armengaud MH, Freund F, Dalibart R, Moze E, Huet S, et al. Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein. Leukemia. 1997;11(Suppl. 3):38–41.PubMed

31.

Hadlock KG, Rowe J, Perkins S, Bradshaw P, Song GY, Cheng C, et al. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J Virol. 1997;71:5828–40.PubMed

32.

Hadlock KG, Rowe J, Foung SK. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes. J Virol. 1999;73:1205–12.PubMed

33.

Takahashi K, Takezaki T, Oki T, Kawakami K, Yahiski S, Fujiyoshi T, et al. Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. Int J Cancer. 1991;49:673–7.PubMedCrossRef

34.

Kazanji M, Heraud JM, Merien F, Pique C, de The G, Gessain A, Jacobson S, et al. Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunized squirrel monkeys (Saimiri sciureus). J Gen Virol. 2006;87:1331–7.PubMedCrossRef

35.

Kazanji M, Tartaglia J, Franchini G, de Thoisy B, Talarmin A, Contamin H, Gessain A, de The G, et al. Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). J Virol. 2001;75:5939–48.PubMedCrossRef

36.

Kerkhofs P, Gatot JS, Knapen K, Mammerickx M, Burny A, Portetelle D, Willems L, Kettmann R. Long-term protection against bovine leukaemia virus replication in cattle and sheep. J Gen Virol. 2000;81:957–63.PubMed

Title: Current status of HTLV-1 infection
Author: Toshiki Watanabe
Publication date: 01-11-2011
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-011-0934-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Molecular mechanisms of HTLV-1 infection and pathogenesis

Successful allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease with inflammatory complications and severe infection

MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis

Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder

Motor disability in the setting of oral anticoagulant therapy

The challenges of adherence and persistence with iron chelation therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer